0
Special Section Papers

A Study of the External Exposure Decay Curves as a Function of Several Clinical Parameters for Patients Treated With Therapeutic 131I

[+] Author and Article Information
Dimitry Ginzburg

Radiation Detection Department,
Rotem Industries, Ltd.,
Rotem Industrial Park,
Mishor Yamin D.N. Arava
8680600, Israel
e-mail: dimgiz@rotemi.co.il

Sophia Lantsberg

Institute of Nuclear Medicine,
Soroka University Medical Center,
Beer Sheva 84101, Israel
e-mail: SophieL@clalit.org.il

Sergio Faermann

Dosimetry/Radiation Protection,
Tel Aviv 6935645, Israel
e-mail: sergio@post.bgu.ac.il

1Corresponding author.

Manuscript received August 30, 2016; final manuscript received April 2, 2017; published online May 25, 2017. Assoc. Editor: Jean Koch.

ASME J of Nuclear Rad Sci 3(3), 030906 (May 25, 2017) (4 pages) Paper No: NERS-16-1095; doi: 10.1115/1.4036433 History: Received August 30, 2016; Revised April 02, 2017

Hyperthyroid and thyroid carcinoma patients treated with radioactive 131I (RAI) are a potential source of external and internal exposure to members of the public, to medical staff and especially to family members, who are in close contact with these patients. The relationship between radiation dose rates and various clinical parameters, including gender, age, thyroid size and weight, and iodine uptake, was assessed. Dose rates were measured on eight patients with thyroid carcinoma after total or subtotal thyroidectomy and on six patients with hyperthyroidism. All measurements were taken at 1 m from the patient on two levels—anterior to the neck and body center. Dose rates were measured at three or four times—at the time of RAI administration, and after 24 h, 48 h, and 168 h. Based on these measurements, retention curves were obtained. The effective half-life was derived by fitting an exponential equation and was estimated to be 12.8 h.

FIGURES IN THIS ARTICLE
<>
Copyright © 2017 by ASME
Your Session has timed out. Please sign back in to continue.

References

Figures

Grahic Jump Location
Fig. 1

Average dose rate versus time measured from patients with thyroid cancer at 1 m anterior to the neck and to the body center. The bold line corresponds to the dose rate under which the Regulatory Guide of the Israeli Ministry of Health allows release of the patient from the hospital.

Grahic Jump Location
Fig. 2

Dose rate as a function of time and gender of the patients with thyroid cancer

Grahic Jump Location
Fig. 3

Dose rate as a function of time and age of the patients with thyroid cancer

Grahic Jump Location
Fig. 4

Dose rate as a function of time and gender of the patients with hyperthyroidism

Grahic Jump Location
Fig. 5

Dose rate as a function of time and uptake for patients with hyperthyroidism

Grahic Jump Location
Fig. 6

Dose rate as a function of time and age of the patients with hyperthyroidism

Tables

Errata

Discussions

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging and repositioning the boxes below.

Related Journal Articles
Related eBook Content
Topic Collections

Sorry! You do not have access to this content. For assistance or to subscribe, please contact us:

  • TELEPHONE: 1-800-843-2763 (Toll-free in the USA)
  • EMAIL: asmedigitalcollection@asme.org
Sign In